Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Renal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Renal Cancer
    TopAbstracts in Renal Cancer 11/17/2008 - (DGNews)
    TopAbstracts in Renal Cancer 11/12/2008 - (DGNews)
    Darbepoetin Alfa Requires Fewer Dosing Changes Than Epoetin Alfa: Presented at ASN - (DGDispatch)
    Aggressive, Personalised Treatment Increases Kidney Cancer Patient Survival - (DGNews)
    Therapy Targeting Vascular Endothelial Growth Factor Receptor-1 Useful in Treating Human Renal Carcinoma: Presented at EORTC-NCI-AACR - (DGDispatch)

    News archive

     Recent webcasts/CME - Renal Cancer
    • Targeted Therapies Show Activity as First-Line Treatment of Renal Cell Carcinoma
    • Emerging Therapies and Combination Therapy as the Future of Renal Cell Carcinoma Treatment
    • Utilizing and Improving Prognostic Markers in Determining Best Treatment of Renal Cell Carcinoma
    • Targeted Agents Recommended for Renal Cell Carcinoma Therapy
    • New Science and Therapeutic Advances in the Treatment of Renal Cell Carcinoma: A Case Study Review

      Webcasts/CME archive

       Recent cases - Renal Cancer
        Oral Cavity Metastasis of Renal Cell Carcinoma: A Case Report
        Solitary Intrathyroidal Metastasis of Renal Clear Cell Carcinoma in a Toxic Substernal Multinodular Goiter
        Short-Term Effective Treatment of CNS Metastasis of Sarcomatoid Renal Cell Carcinoma with Temozolomide and Pegylated Liposomal Doxorubicin: A Case Report
        Primitive Neuroectodermal Tumour of the Kidney with Vena Caval and Atrial Tumour Thrombus: A Case Report
        Tongue Metastasis as an Initial Presentation of Renal Cell Carcinoma: A Case Report and Literature Review

        Cases archive
          




        my personal edition > renal cancer > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Guideline for Cutoff Size For Stage I Renal Cell Carcinoma Should Be Lowered

        A DGReview of :"Reassessment of the 1997 TNM classification system for renal cell carcinoma"
        Cancer

        12/04/2003
        By Emma Hitt, PhD


        The Tumor, Nodes, Metastases (TNM) cutoff of 7.0 cm used to separate Stage I from Stage II renal cell carcinoma (RCC) appears to be too high, according to a new report. Instead, a 5.0 cm cutoff appears to stratify size-related survival difference more accurately.

        In 1997, the TNM classification of malignant tumour size cutoff between T1 and T2 organ-confined RCC was changed from 2.5 cm to 7.0 cm; however, several investigators have claimed that 7.0 cm may be too high.

        Therefore, James M. Elmore, MD, with the University of Texas Southwestern Medical Center, Dallas, United States, and colleagues evaluated the validity of this cutoff size by assessing the survival of patients with Stage I RCC according to a series of alternative size cutoff values. They also determined how these size cutoffs affected the risk of having nonorgan-confined tumours, regional lymph node involvement, and metastatic disease.

        The researchers evaluated a database containing the records of 1,324 patients with RCC who underwent open radical nephrectomy between 1960 and 1991. Patients with Stage I disease were stratified by size cutoffs ranging from 2.5 to 7.0 cm in 0.5-cm increments.

        A total of 351 out of 544 evaluable patients had tumours of 7.0 cm or smaller, and 233 of these patients had 1997 Stage I (T1N0M0) disease.

        When patients with 1997 Stage I tumours were separated based on tumour size, a 5.0-cm cutoff resulted in the most difference in survivals. The 5-year DSS rates for patients with Stage I tumours 5 cm or smaller versus those with tumours measuring 5.1-7 cm were 94.6% versus 79.2% (P = .003). Furthermore, the survival of patients with Stage I RCC lesions measuring 5.1-7.0 cm was the same as for patients with 1997 Stage II (T2N0M0) RCC.

        The difference in probability of having local nonorgan-confined disease was also greatest with a 5.0 cm cutoff value (present in 16.2% of the patients with tumours smaller than 5.0 cm compared with 36.8% of the patients with tumours measuring 5.1-7.0 cm in size), which may have an impact on nephron-sparing surgery in selected patients, the authors note.

        The difference in the probabilities of having lymph node-positive or metastatic disease did not change significantly using any of the cutoffs, although the probability of both of these increased with increasing tumour size, they report.

        "The current study findings, as well as those of others, support a size cutoff for Stage I RCC between 4 cm and 5 cm," the researchers conclude.

        Cancer 2003;98:2329-2334. "Reassessment of the 1997 TNM classification system for renal cell carcinoma"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send